Could Abrocitinib Modify Atopic Dermatitis Disease Course?

For most patients with moderate to severe atopic dermatitis (AD), systemic therapy is understood to be long-term, a tool for ongoing disease control rather than a path toward remission.¹ However, emerging data are beginning to challenge that assumption, raising the possibility that a subset of patients may achieve meaningful, sustained disease control even after treatment is stopped.

New findings from a post hoc analysis of the phase 3 JADE REGIMEN (NCT03627767) trial, presented at the 2026 Winter Clinical Dermatology Conference in Hawaii, add important evidence to that conversation.¹ The analysis examined outcomes in patients with moderate to severe AD who completed 12 weeks of open-label, once-daily abrocitinib 200 mg induction therapy and were then randomly assigned to a 40-week maintenance regimen of continued abrocitinib, dose reduction, or placebo. Among the 267 patients randomly assigned to placebo (representing complete dose withdrawal), approximately 22% did not experience a protocol-defined flare, and their Eczema Area and Severity Index, Investigator Global Assessment, Peak Pruritus Numerical Rating Scale, and Dermatology Life Quality Index scores remained stable in the clear to mild range throughout the 40-week period.²

Emma Guttman-Yassky, MD, PhD, of the Icahn School of Medicine at Mount Sinai, Dermatology Times editorial advisory board member, and a lead author on the analysis, talked with our editors to discuss what these findings mean for how the field conceptualizes disease remission, which patients might be candidates for treatment interruption, and what biomarker research could reveal about the biology driving off-treatment durability.

Q&A

How are you defining disease remission in this analysis, and do you think the field overall is ready for a standardized definition?

Typically, we are thinking about minimal disease activity; that's where the field is evolving. Minimal disease activity is defined by both the physician and the patient. I think in the future, we'll see more and more studies that identify minimal disease activity, because what it does is push the efficacy bar a little bit further. It's not only one outcome; it incorporates both the physician and patient perspectives, and it really raises the standard.

Do you think the 12-week findings represent disease-modifying effects or more of a prolonged pharmacologic effect?

That's a great question. I think we need more time to really understand this. But it's possible that there is a subset of patients—those with more moderate disease—for whom having a systemic treatment is truly disease-modifying. I don't think we can say the verdict on that yet. We need to wait and see.

What do you think distinguishes patients who maintain disease control off therapy from those who don't?

Right now, we don't have that answer, but we are doing biomarker work and studies in the lab to try to understand responders—the mega responders vs the regular responders. We really want to understand those super responders.

In practice, outside a clinical trial, how do you decide when it’s safe to stop or taper a therapy given the risk of a flare?

I'm not somebody who stops therapy altogether. It's always a negotiation with the patient. For patients who are very well controlled, I might allow them to skip the drug 1 or 2 times a week—take it a few times a week rather than daily—but I would not stop it altogether.

What do you see as the next most important step in this space—biomarker discovery, remission trials, or something else?

I do think biomarkers are important, particularly now that we have tape strips that are easy to use and more than minimally invasive. You can take them longitudinally—at baseline, 12 weeks, 6 months, a year, and even longer—to really understand what's happening during treatment and what's happening when you stop. That kind of longitudinal biomarker data [will] be critical.

This transcript has been edited for clarity.

For more atopic dermatitis news and research, register to attend the 2026 Revolutionizing Atopic Dermatitis (RAD) conference in Nashville, Tennessee, held June 17-19. Use code DT40 for 40% off registration.

References

1. Paller AS, Marcoux D, Ramien M, et al. Systemic treatments in moderate-to-severe atopic dermatitis in pediatric patients up to 12 years of age: real-world treatment outcomes from the PEDISTAD registry. Am J Clin Dermatol. 2025;26(6):1031-1043. doi:10.1007/s40257-025-00962-8
2. Guttman-Yassky E, Bieber T, Gutermuth J, et al. Sustained on- and off-treatment disease control in patients with moderate-to-severe atopic dermatitis following 12-week, open-label, once-daily abrocitinib 200 mg: a post hoc analysis of the phase 3 JADE REGIMEN study. J of Skin. 2026;10(2):s732. doi:10.25251/v9pqj003